Santiago Arroyo, M.D., Ph.D.
Chief Development Officer

Santiago Arroyo, M.D., Ph.D., is the chief development officer of Bicycle Therapeutics.

Santiago was most recently the chief medical officer of Fulcrum Therapeutics. Previously, he was chief medical officer of Momenta Pharmaceuticals culminating in the acquisition by Johnson & Johnson for $6.5 billion in 2020. As chief medical officer at Momenta, he led the clinical development of the company’s portfolio of hematology, neurology, immunology, and materno-fetal therapeutics. Previously, he was the chief medical officer of Boston Pharmaceuticals and before that held multiple senior clinical development leadership roles at leading pharmaceutical companies. Santiago served as senior vice president, head of clinical research and chief medical officer of pharmatherapeutics at Pfizer, and was the therapeutic area head for neurosciences, discovery medicine and clinical pharmacology at Bristol-Myers Squibb. Earlier, he held clinical development roles at Eisai Global Clinical Development and Schwarz Biosciences.

Santiago was an instructor at the Johns Hopkins Medical School, an associate professor at the Medical College of Wisconsin and a senior specialist at the Hospital Clinic of Barcelona. He earned a Ph.D. from the Universidad de Barcelona and an M.D. from the Universidad Autonóma de Madrid. Finally, he is a non-executive director of Lundbeck and GlycoEra AG.